Navigation Links
Publication of Shire plc's Annual Report 2008
Date:3/25/2009

roval in the EU.

LIALDA/MEZAVANT for the treatment of diverticulitis

Phase 3 worldwide clinical trials investigating the use of the product for the treatment of diverticulitis were initiated in 2007 and are continuing.

SPD550 (Larazotide Acetate; also known as AT-1001) for the treatment of Celiac disease

SPD550 is being developed for the treatment of Celiac disease. In December 2007 Shire acquired the worldwide rights to SPD550 (Larazotide Acetate; also known as AT-1001) in markets outside of the US and Japan from Alba. The two parties have established Joint Committees which will guide the development, manufacture and commercialization of the product. Alba has initiated and is responsible for executing the ongoing Phase 2 program and certain non-clinical studies. Additional development studies may be conducted jointly or by the individual companies prior to or after initiation of Phase 3.

Treatments for diseases in other therapeutic areas

FOSRENOL for the treatment of pre-dialysis chronic kidney disease ('CKD')

Following the FDA Cardiovascular and Renal Drugs Advisory Committee recommendation in October of 2007 on the use of phosphate binders, including FOSRENOL, to treat hyperphosphatemia in pre-dialysis CKD patients, Shire continues to work with the FDA to determine whether FOSRENOL can launch in the pre-dialysis CKD market in the US without conducting additional clinical outcomes trials.

JUVISTA

Renovo Limited ('Renovo') initiated its first pivotal European Phase 3 trial in scar revision in the fourth quarter of 2008 to support the filing of a European regulatory dossier. If the outcome from Renovo's multi centre, EU Phase 3 study is suitably positive, the data will be used to inform the strategy and design of Shire's US development plan and to strengthen the chances of regulatory and commercial success in the US.


'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM)
2. Sopherion Therapeutics, LLC Announces Publication of Phase I/II Myocet(R) (Nonpegylated Liposomal Doxorubicin) Data in Advanced Breast Cancer Patients
3. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
4. BioTrends Releases TreatmentTrends(TM): US Nephrology, an Ongoing Syndicated Publication Providing Insight into Physician Perceptions and Management of Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
5. New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases
6. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
7. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
8. Genomic Health Announces Publication of a Study Demonstrating the Oncotype DX(R) Breast Cancer Assay Influences Chemotherapy Treatment Recommendation in 44 Percent of Patients Evaluated
9. Publication on Tregitopes in Blood Journal of October 2008
10. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
11. ABMAC Foundation Announces Publication of an Historic Volume Documenting the Creation of a National Health Care System in Taiwan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Bellingham, WA (PRWEB) May 24, 2013 ... researchers, engineers, and industry suppliers will present technologies ... life at the annual SPIE Optics and ... August. Organized by SPIE, the international society ... the largest international, multidisciplinary optical sciences and technology ...
(Date:5/24/2013)... Many factors impact tissues targeting such ... transporters at the blood-tissue barrier. Even when tissue disposition ... in the tissue rather than the total tissue concentration. ... required to guide lead optimization, predict in vivo activity ... that may impact the likely human clinical dose. , ...
(Date:5/23/2013)... stopped breathing, his collapsed bronchus blocking the crucial flow ... watched helplessly, just praying that somehow the dire predictions ... had a good chance of not leaving the hospital ... Kaiba. "At that point, we were desperate. Anything that ... it." , They found hope at the University of ...
(Date:5/23/2013)... Patheon Inc ., a leading provider of ... industry, will host a complimentary webinar on “Cleaning Validation: ... June 4, 2013 at 11 a.m. Eastern Standard Time. ... with regulations for cleaning validation. Many companies have ... little evaluation of risk. Some companies have chosen ...
Breaking Biology Technology:See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 2See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 3See What’s in Earth’s Future ? and Out in Space Now ? at SPIE Optics and Photonics 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 2Baby's life saved with groundbreaking 3-D printed device that restored his breathing 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2
... Biomarker Identification ... and ADME/Tox Applications, LINCOLN, R.I., ... into a worldwide,exclusive license and technology purchase agreement with Corning,Incorporated ... cell lines. Corning paid MultiCell a license fee, and ...
... of Unsaturated Fatty Acids in ... Cardiovascular ... AMRN ) today announced that it has initiated a cardiovascular,development ... acids in cardiovascular disease. Amarin plans to utilize,its extensive know-how ...
... Fourth Fourth Fiscal Fiscal ($ in millions) ... ... $364 $212 $2,807 $1,793 Soybean seed and traits ... Cotton seed and traits 58 52 319 ...
Cached Biology Technology:MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated 2MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated 3Amarin Announces Initiation of Cardiovascular Development Strategy 2Amarin Announces Initiation of Cardiovascular Development Strategy 3Amarin Announces Initiation of Cardiovascular Development Strategy 4Amarin Announces Initiation of Cardiovascular Development Strategy 5Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 2Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 3Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 4Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 5Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 6Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 7Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 8Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 9Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 10Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 11Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 12Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 13Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 14Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 15Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 16Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 17Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results 18
(Date:5/22/2013)... a novel technique that can detect molecular variants in ... one of the most important, though time-consuming, processes in ... in Nature , post-doctoral researcher David Patterson, Professor ... the Center for Free-Electron Laser Science (CFEL) in Hamburg, ... fields to identify molecular variants apart, and to determine ...
(Date:5/22/2013)... 3 fatty acids in fish oil have long been ... the American Heart Association currently recommends eating at least ... rich in omega 3s. However, the mechanism behind this ... study, scientists led by Jason R. Carter of Michigan ... evidence that fish oil might specifically counteract the detrimental ...
(Date:5/22/2013)... and human health effects from disposal of millions ... scientists to recommend stronger government policies to encourage ... materials. That,s the conclusion of a new paper ... Technology . , Oladele A. Ogunseitan and colleagues ... for powering everything from smart phones to components ...
Breaking Biology News(10 mins):Detecting mirror molecules 2Detecting mirror molecules 3Fish oil may help the heart beat mental stress 2
... A new discovery about selective serotonin reuptake inhibitors ... treat mental health disorders like depression and anxiety, have ... published in the August 2010 issue of GENETICS ... identify secondary drug targets or pathways affected by SSRIs. ...
... Solitary snails in search of a mate put off parenthood as ... But when Physa acuta snails smell predators, they don,t ... parenthood much sooner than their calm counterparts, says a new study ... Durham, NC. "They can,t wait for a mate indefinitely ...
... Buck Institute for Age Research have successfully used human ... with Parkinson,s Disease (PD). The research, which validates ... developed, can be used to manufacture the type of ... way for the use of iPSC,s in various biomedical ...
Cached Biology News:SSRIs may pack more punch at the cellular level than believed 2Scared snails opt for single parenthood rather than wait for a mate 2Scientists successfully use human induced pluripotent stem cells to treat Parkinson's in rodents 2
Mouse monoclonal antibody raised against a full length recombinant SLC25A11. NCBI Entrez Gene ID = SLC25A11...
... raised against a partial recombinant ... TOPORS (NP_005793, 98 a.a. ... protein with GST tag. ... NM_005802 Protein ...
Mouse monoclonal antibody raised against a full length recombinant SNAPC5. NCBI Entrez Gene ID = SNAPC5...
... antibody raised against a partial recombinant NFKBIB. ... ~ 145 a.a) partial recombinant protein with GST ... Accession: BC015528 ... OMIM: 604495, GeneID: ...
Biology Products: